3. Patients who are on standard ALL maintenance type chemotherapy (vincristine, 6- mercaptopurine or oral methotrexate or a tyrosine kinase inhibitor for patients with Ph+ ALL) may be enrolled provided that chemotherapy is discontinued at least 1 week prior to apheresis.